Trial Outcomes & Findings for Hemodynamic Response of Neuropathic And Non-Neuropathic POTS Patients To Adrenoreceptor Agonist And Antagonist (NCT NCT03070730)
NCT ID: NCT03070730
Last Updated: 2017-05-18
Results Overview
Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test.
Recruitment status
TERMINATED
Study phase
PHASE1/PHASE2
Target enrollment
8 participants
Primary outcome timeframe
Up to 3 days after randomization
Results posted on
2017-05-18
Participant Flow
Participants that were enrolled in the study were excluded from the study because they either did not meet eligibility criteria or decided not to participate.
Participant milestones
| Measure |
Atenolol
In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
Placebos
In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d
|
Droxidopa
In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
|---|---|---|---|
|
Overall Study
STARTED
|
0
|
0
|
0
|
|
Overall Study
COMPLETED
|
0
|
0
|
0
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Hemodynamic Response of Neuropathic And Non-Neuropathic POTS Patients To Adrenoreceptor Agonist And Antagonist
Baseline characteristics by cohort
| Measure |
Atenolol
In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
Placebos
In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d
|
Droxidopa
In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
Total
Total of all reporting groups
|
|---|---|---|---|---|
|
Age, Customized
|
0
n=5 Participants
|
0
n=7 Participants
|
0
n=5 Participants
|
—
|
|
Sex: Female, Male
Female
|
0
n=5 Participants
|
0
n=7 Participants
|
0
n=5 Participants
|
—
|
|
Sex: Female, Male
Male
|
0
n=5 Participants
|
0
n=7 Participants
|
0
n=5 Participants
|
—
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0
n=5 Participants
|
0
n=7 Participants
|
0
n=5 Participants
|
0
n=4 Participants
|
|
Race (NIH/OMB)
Asian
|
0
n=5 Participants
|
0
n=7 Participants
|
0
n=5 Participants
|
0
n=4 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0
n=5 Participants
|
0
n=7 Participants
|
0
n=5 Participants
|
0
n=4 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0
n=5 Participants
|
0
n=7 Participants
|
0
n=5 Participants
|
0
n=4 Participants
|
|
Race (NIH/OMB)
White
|
0
n=5 Participants
|
0
n=7 Participants
|
0
n=5 Participants
|
0
n=4 Participants
|
|
Race (NIH/OMB)
More than one race
|
0
n=5 Participants
|
0
n=7 Participants
|
0
n=5 Participants
|
0
n=4 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0
n=5 Participants
|
0
n=7 Participants
|
0
n=5 Participants
|
0
n=4 Participants
|
PRIMARY outcome
Timeframe: Up to 3 days after randomizationMaximal postural tachycardia is the maximum heart rate during a 20-min tilt table test.
Outcome measures
| Measure |
Atenolol
In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
Placebos
In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d
|
Droxidopa
In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
|---|---|---|---|
|
Change in Maximal Postural Tachycardia During Tilt
|
0
|
0
|
0
|
PRIMARY outcome
Timeframe: 2 weeks after first interventionMaximal postural tachycardia is the maximum heart rate during a 20-min tilt table test.
Outcome measures
| Measure |
Atenolol
In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
Placebos
In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d
|
Droxidopa
In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
|---|---|---|---|
|
Change Maximal Postural Tachycardia During Tilt
|
0
|
0
|
0
|
PRIMARY outcome
Timeframe: 2 weeks after second interventionMaximal postural tachycardia is the maximum heart rate during a 20-min tilt table test.
Outcome measures
| Measure |
Atenolol
In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
Placebos
In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d
|
Droxidopa
In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
|---|---|---|---|
|
Change Maximal Postural Tachycardia During Tilt
|
0
|
0
|
0
|
PRIMARY outcome
Timeframe: up to 3 days after randomizationA 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue.
Outcome measures
| Measure |
Atenolol
In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
Placebos
In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d
|
Droxidopa
In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
|---|---|---|---|
|
Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline
|
0
|
0
|
0
|
PRIMARY outcome
Timeframe: 2 weeks after first interventionA 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue.
Outcome measures
| Measure |
Atenolol
In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
Placebos
In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d
|
Droxidopa
In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
|---|---|---|---|
|
Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline
|
0
|
0
|
0
|
PRIMARY outcome
Timeframe: 2 weeks after second interventionA 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue.
Outcome measures
| Measure |
Atenolol
In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
Placebos
In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d
|
Droxidopa
In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
|---|---|---|---|
|
Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline
|
0
|
0
|
0
|
SECONDARY outcome
Timeframe: 1 week after first interventionOutcome measures
| Measure |
Atenolol
In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
Placebos
In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d
|
Droxidopa
In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
|---|---|---|---|
|
Change in Blood Pressure From Baseline
|
0
|
0
|
0
|
SECONDARY outcome
Timeframe: 1 week after second interventionOutcome measures
| Measure |
Atenolol
In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
Placebos
In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d
|
Droxidopa
In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
|---|---|---|---|
|
Change in Blood Pressure From Baseline
|
0
|
0
|
0
|
SECONDARY outcome
Timeframe: 1 week after third interventionOutcome measures
| Measure |
Atenolol
In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
Placebos
In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d
|
Droxidopa
In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
|---|---|---|---|
|
Change in Blood Pressure From Baseline
|
0
|
0
|
0
|
SECONDARY outcome
Timeframe: 1 week after first interventionOutcome measures
| Measure |
Atenolol
In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
Placebos
In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d
|
Droxidopa
In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
|---|---|---|---|
|
Change in Heart Rate From Baseline
|
0
|
0
|
0
|
SECONDARY outcome
Timeframe: 1 week after second interventionOutcome measures
| Measure |
Atenolol
In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
Placebos
In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d
|
Droxidopa
In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
|---|---|---|---|
|
Change in Heart Rate From Baseline
|
0
|
0
|
0
|
SECONDARY outcome
Timeframe: 1 week after third interventionOutcome measures
| Measure |
Atenolol
In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
Placebos
In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d
|
Droxidopa
In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
|---|---|---|---|
|
Change in Heart Rate From Baseline
|
0
|
0
|
0
|
SECONDARY outcome
Timeframe: 1 week after first interventionOutcome measures
| Measure |
Atenolol
In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
Placebos
In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d
|
Droxidopa
In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
|---|---|---|---|
|
Change in Vascular Resistance From Baseline
|
0
|
0
|
0
|
SECONDARY outcome
Timeframe: 1 week after second interventionOutcome measures
| Measure |
Atenolol
In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
Placebos
In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d
|
Droxidopa
In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
|---|---|---|---|
|
Change in Vascular Resistance From Baseline
|
0
|
0
|
0
|
SECONDARY outcome
Timeframe: 1 week after third interventionOutcome measures
| Measure |
Atenolol
In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
Placebos
In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d
|
Droxidopa
In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
|---|---|---|---|
|
Change in Vascular Resistance From Baseline
|
0
|
0
|
0
|
SECONDARY outcome
Timeframe: 1 week after first interventionOutcome measures
| Measure |
Atenolol
In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
Placebos
In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d
|
Droxidopa
In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
|---|---|---|---|
|
Change in Muscle Sympathetic Nerve Activity From Baseline
|
0
|
0
|
0
|
SECONDARY outcome
Timeframe: 1 week after second interventionOutcome measures
| Measure |
Atenolol
In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
Placebos
In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d
|
Droxidopa
In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
|---|---|---|---|
|
Change in Muscle Sympathetic Nerve Activity From Baseline
|
0
|
0
|
0
|
SECONDARY outcome
Timeframe: 1 week after third interventionOutcome measures
| Measure |
Atenolol
In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
Placebos
In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d
|
Droxidopa
In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
|---|---|---|---|
|
Change in Muscle Sympathetic Nerve Activity From Baseline
|
0
|
0
|
0
|
SECONDARY outcome
Timeframe: 1 week after first interventionMeasures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire.
Outcome measures
| Measure |
Atenolol
In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
Placebos
In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d
|
Droxidopa
In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
|---|---|---|---|
|
Change in Physical Functioning-SF-36 Q From Baseline
|
0
|
0
|
0
|
SECONDARY outcome
Timeframe: 1 week after second interventionMeasures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire.
Outcome measures
| Measure |
Atenolol
In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
Placebos
In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d
|
Droxidopa
In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
|---|---|---|---|
|
Change in Physical Functioning-SF-36 Q From Baseline
|
0
|
0
|
0
|
SECONDARY outcome
Timeframe: 1 week after third interventionMeasures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire.
Outcome measures
| Measure |
Atenolol
In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
Placebos
In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d
|
Droxidopa
In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
|---|---|---|---|
|
Change in Physical Functioning-SF-36 Q From Baseline
|
0
|
0
|
0
|
SECONDARY outcome
Timeframe: 1 week after first interventionMeasures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better" to "very much worse".
Outcome measures
| Measure |
Atenolol
In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
Placebos
In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d
|
Droxidopa
In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
|---|---|---|---|
|
Change in Physical Functioning- 7 Item Patient Global Impression of Change From Baseline
|
0
|
0
|
0
|
SECONDARY outcome
Timeframe: 1 week after second interventionMeasures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better" to "very much worse".
Outcome measures
| Measure |
Atenolol
In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
Placebos
In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d
|
Droxidopa
In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
|---|---|---|---|
|
Change in Physical Functioning- 7 Item Patient Global Impression of Change From Baseline
|
0
|
0
|
0
|
SECONDARY outcome
Timeframe: 1 week after third interventionMeasures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better" to "very much worse".
Outcome measures
| Measure |
Atenolol
In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
Placebos
In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d
|
Droxidopa
In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
|---|---|---|---|
|
Change in Physical Functioning- 7 Item Patient Global Impression of Change From Baseline
|
0
|
0
|
0
|
SECONDARY outcome
Timeframe: 1 week after first interventionMeasures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales.
Outcome measures
| Measure |
Atenolol
In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
Placebos
In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d
|
Droxidopa
In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
|---|---|---|---|
|
Change in Physical Functioning- HADS From Baseline
|
0
|
0
|
0
|
SECONDARY outcome
Timeframe: 1 week after second interventionMeasures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales.
Outcome measures
| Measure |
Atenolol
In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
Placebos
In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d
|
Droxidopa
In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
|---|---|---|---|
|
Change in Physical Functioning- HADS From Baseline
|
0
|
0
|
0
|
SECONDARY outcome
Timeframe: 1 week after third interventionMeasures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales.
Outcome measures
| Measure |
Atenolol
In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
Placebos
In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d
|
Droxidopa
In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
|---|---|---|---|
|
Change in Physical Functioning- HADS From Baseline
|
0
|
0
|
0
|
SECONDARY outcome
Timeframe: 1 week after first interventionMeasures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS).
Outcome measures
| Measure |
Atenolol
In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
Placebos
In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d
|
Droxidopa
In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
|---|---|---|---|
|
Change in Physical Functioning-CIS From Baseline
|
0
|
0
|
0
|
SECONDARY outcome
Timeframe: 1 week after second interventionMeasures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS).
Outcome measures
| Measure |
Atenolol
In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
Placebos
In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d
|
Droxidopa
In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
|---|---|---|---|
|
Change in Physical Functioning-CIS From Baseline
|
0
|
0
|
0
|
SECONDARY outcome
Timeframe: 1 week after third interventionMeasures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS).
Outcome measures
| Measure |
Atenolol
In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
Placebos
In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d
|
Droxidopa
In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
|---|---|---|---|
|
Change in Physical Functioning-CIS From Baseline
|
0
|
0
|
0
|
SECONDARY outcome
Timeframe: 1 week after first interventionMeasures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI).
Outcome measures
| Measure |
Atenolol
In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
Placebos
In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d
|
Droxidopa
In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
|---|---|---|---|
|
Change in Physical Functioning-MFI From Baseline
|
0
|
0
|
0
|
SECONDARY outcome
Timeframe: 1 week after second interventionMeasures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI).
Outcome measures
| Measure |
Atenolol
In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
Placebos
In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d
|
Droxidopa
In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
|---|---|---|---|
|
Change in Physical Functioning-MFI From Baseline
|
0
|
0
|
0
|
SECONDARY outcome
Timeframe: 1 week after third interventionMeasures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI).
Outcome measures
| Measure |
Atenolol
In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
Placebos
In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d
|
Droxidopa
In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
|---|---|---|---|
|
Change in Physical Functioning-MFI From Baseline
|
0
|
0
|
0
|
SECONDARY outcome
Timeframe: 1 week after first interventionMeasures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale.
Outcome measures
| Measure |
Atenolol
In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
Placebos
In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d
|
Droxidopa
In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
|---|---|---|---|
|
Change in Physical Functioning-FSS From Baseline
|
0
|
0
|
0
|
SECONDARY outcome
Timeframe: 1 week after second interventionMeasures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale.
Outcome measures
| Measure |
Atenolol
In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
Placebos
In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d
|
Droxidopa
In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
|---|---|---|---|
|
Change in Physical Functioning-FSS From Baseline
|
0
|
0
|
0
|
SECONDARY outcome
Timeframe: 1 week after third interventionMeasures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale.
Outcome measures
| Measure |
Atenolol
In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
Placebos
In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d
|
Droxidopa
In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
|---|---|---|---|
|
Change in Physical Functioning-FSS From Baseline
|
0
|
0
|
0
|
SECONDARY outcome
Timeframe: 1 week after first interventionMeasures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL.
Outcome measures
| Measure |
Atenolol
In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
Placebos
In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d
|
Droxidopa
In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
|---|---|---|---|
|
Change in Physical Functioning-EuroQOL From Baseline
|
0
|
0
|
0
|
SECONDARY outcome
Timeframe: 1 week after second interventionMeasures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL.
Outcome measures
| Measure |
Atenolol
In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
Placebos
In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d
|
Droxidopa
In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
|---|---|---|---|
|
Change in Physical Functioning-EuroQOL From Baseline
|
0
|
0
|
0
|
SECONDARY outcome
Timeframe: 1 week after third interventionMeasures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL.
Outcome measures
| Measure |
Atenolol
In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
Placebos
In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d
|
Droxidopa
In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
|---|---|---|---|
|
Change in Physical Functioning-EuroQOL From Baseline
|
0
|
0
|
0
|
SECONDARY outcome
Timeframe: 1 week after first interventionMeasures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire.
Outcome measures
| Measure |
Atenolol
In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
Placebos
In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d
|
Droxidopa
In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
|---|---|---|---|
|
Change in Physical Functioning-OI From Baseline
|
0
|
0
|
0
|
SECONDARY outcome
Timeframe: 1 week after second interventionMeasures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire.
Outcome measures
| Measure |
Atenolol
In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
Placebos
In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d
|
Droxidopa
In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
|---|---|---|---|
|
Change in Physical Functioning-OI From Baseline
|
0
|
0
|
0
|
SECONDARY outcome
Timeframe: 1 week after third interventionMeasures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire.
Outcome measures
| Measure |
Atenolol
In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
Placebos
In this arm subjects are randomized to placebo tid.
Placebo is used to control the administration effect.
Placebos: Placebo: t.i.d
|
Droxidopa
In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.
Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.
Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients.
Droxidopa: Droxidopa: 100 mg or 300 mg t.i.d
Atenolol: Atenolol: 50 mg Q.D.
Placebos: Placebo: t.i.d
|
|---|---|---|---|
|
Change in Physical Functioning-OI From Baseline
|
0
|
0
|
0
|
Adverse Events
Atenolol
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Placebos
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Droxidopa
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place